Does older age reduce immune resilience?

Older age is reliably associated with lower immune resilience at the population level. For a 71-year-old, this does not imply immune failure, but it does increase the relevance of vaccination history, frailty, comorbidity, chronic infection, and medications when estimating infection and vaccine-response risk.

Clinical and immunologic evidence

• Age-related immunosenescence is strongly supported by human studies. A systematic review of healthy adults found naïve CD8+ T-cell frequencies were 33.86 percentage points higher in younger than older adults (95% CI 28.40–39.32), consistent with substantial adaptive-immune remodeling.
• Clinically, older adults have greater susceptibility to severe influenza, RSV, pneumococcal disease, and COVID-19 and often show less robust, less durable antibody and cellular vaccine responses. Many still mount substantial responses, particularly after additional vaccine doses; in some SARS-CoV-2 cohorts, a third dose reduced apparent age- and frailty-related differences.

Mechanisms

• Progressive thymic involution reduces thymopoiesis and peripheral naïve T-cell output. Together with reduced T-cell receptor diversity and accumulation of differentiated/exhausted memory populations, this narrows the capacity to recognize unfamiliar antigens.
• Ageing also affects B-cell function, antigen presentation, and innate immune coordination.
• “Inflammaging”—persistent low-grade activation reflected by higher circulating IL-6, TNF-α, and CRP—is well established. Senescent-cell secretory signaling, mitochondrial damage signals, inflammasome/NF-κB activation, adipose dysfunction, altered gut-barrier function, and latent infections may sustain this state.

Interpretation

• Chronic inflammation plausibly worsens immune responsiveness, but its independent causal contribution is less certain: IL-6, TNF-α, and CRP are nonspecific and influenced by adiposity, multimorbidity, medications, frailty, and chronic infection. In one influenza-vaccine trial, higher baseline inflammatory markers correlated with stronger antibody titers, especially with high-dose vaccine.

Bottom line

• The claim is well supported overall: immunosenescence is a major, established contributor to reduced immune resilience with age; chronic low-grade inflammation is a well-established accompanying phenotype with a biologically credible, but less definitively causal, contribution.